EGFR-mutant patients generally have a low response to anti-PD-1/PD-L1 treatment, by mechanisms not yet well understood, but investigations suggest that this resistance is due to low PD-1 expression associated with low tumor mutational burden (TMB) [88]. Here, PDCD1 is linked to neoplasm.